Summit Therapeutics (SMMT) Stock Forecast & Price Target
Score
Summit Therapeutics Inc. price target
| SMMT | |
|---|---|
| Low | $20.00 |
| Average | $32.14 |
| High | $41.00 |
| Upside vs current price | +105.9% |
The average target of $32.14 is +105.9% versus the current SMMT price of $15.61.
Summit Therapeutics Inc. analyst ratings
| Rating | Analysts |
|---|---|
| Strong buy | 1 |
| Buy | 10 |
| Hold | 6 |
| Sell | 0 |
| Strong sell | 0 |
| Consensus | Buy |
17 analysts cover SMMT.
Summit Therapeutics Inc. EPS and revenue estimates
SMMT shows the next fiscal years with at least three analysts: 2026 EPS $-1.12, 2027 EPS $-1.14. A thinner year is left off this table.
| Fiscal year | EPS estimate | Revenue estimate |
|---|---|---|
| 2026 | $-1.12 | $3.46M |
| 2027 | $-1.14 | $58.57M |
Is Summit Therapeutics Inc. a buy or sell?
Of the 17 analysts covering Summit Therapeutics Inc., 11 rate it a buy (1 strong buy and 10 buy), 6 rate it a hold, and 0 rate it a sell (0 sell and 0 strong sell).
The SMMT consensus label is Buy, beside 11 buy-side ratings and 0 sell-side ratings.
The average target of $32.14 implies +105.9% versus the current price of $15.61.
Those 17 ratings on SMMT are a headcount, and the label on file is Buy.
Reading the Summit Therapeutics Inc. forecast
The SMMT target range is wide: $20.00 at the low end, $32.14 in the middle, and $41.00 at the top.
Set next to the $15.61 SMMT quote, that average is +105.9%.
The SMMT ratings are split: 11 of 17 analysts are on the buy side, 6 are at hold, and 0 are on the sell side, and the published consensus is Buy.
Over the last few months SMMT drew 3 upgrades and 0 downgrades.
The SMMT EPS path from 2026 ($-1.12) to 2027 ($-1.14) is rising.
17 analysts publish on SMMT, so one note does not swing the average by itself.
Summit Therapeutics Inc. forecast questions
What is the SMMT price target?
The published range for SMMT is $20.00 to $41.00, with an average of $32.14. That average is +105.9% versus the current price of $15.61.
Is Summit Therapeutics Inc. a buy or sell?
Of the 17 analysts covering Summit Therapeutics Inc., 11 rate it a buy, 6 rate it a hold, and 0 rate it a sell. The consensus is Buy, and the SMMT headcount is 11 buy, 6 hold, and 0 sell.
What is the EPS estimate for Summit Therapeutics Inc.?
Analyst EPS estimates for Summit Therapeutics Inc.: 2026 $-1.12, 2027 $-1.14.
What is the revenue estimate for Summit Therapeutics Inc.?
Analyst revenue estimates for Summit Therapeutics Inc.: 2026 $3.46M, 2027 $58.57M.
How many analysts cover SMMT?
17 analysts cover SMMT. Their consensus on SMMT is Buy, across those 17.